BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11856644)

  • 1. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro.
    Taranta A; Brama M; Teti A; De luca V; Scandurra R; Spera G; Agnusdei D; Termine JD; Migliaccio S
    Bone; 2002 Feb; 30(2):368-76. PubMed ID: 11856644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 17beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth factor-beta1 and insulin-like growth factor-1 in primary human osteoblast cultures.
    Méndez-Dávila C; García-Moreno C; Turbì C; de la Piedra C
    J Endocrinol Invest; 2004 Nov; 27(10):904-12. PubMed ID: 15762036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures.
    Ramalho AC; Couttet P; Baudoin C; Morieux C; Graulet AM; de Vernejoul MC; Cohen-Solal ME
    Eur Cytokine Netw; 2002; 13(1):39-45. PubMed ID: 11956019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
    Michael H; Härkönen PL; Kangas L; Väänänen HK; Hentunen TA
    Br J Pharmacol; 2007 Jun; 151(3):384-95. PubMed ID: 17420779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An estrogen receptor basis for raloxifene action in bone.
    Bryant HU; Glasebrook AL; Yang NN; Sato M
    J Steroid Biochem Mol Biol; 1999; 69(1-6):37-44. PubMed ID: 10418979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells.
    Nuttall ME; Stroup GB; Fisher PW; Nadeau DP; Gowen M; Suva LJ
    Am J Physiol Cell Physiol; 2000 Nov; 279(5):C1550-7. PubMed ID: 11029302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression.
    Narayana Murthy PS; Sengupta S; Sharma S; Singh MM
    J Steroid Biochem Mol Biol; 2006 Aug; 100(4-5):117-28. PubMed ID: 16797179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of genistein, estradiol and raloxifene on rat osteoclasts in vitro.
    Sliwiński L; Folwarczna J; Janiec W; Grynkiewicz G; Kuzyk K
    Pharmacol Rep; 2005; 57(3):352-9. PubMed ID: 15985718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.
    Sliwiński L; Folwarczna J; Nowińska B; Cegieła U; Pytlik M; Kaczmarczyk-Sedlak I; Trzeciak H; Trzeciak HI
    Acta Biochim Pol; 2009; 56(2):261-70. PubMed ID: 19401787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyk2 deficiency potentiates osteoblast differentiation and mineralizing activity in response to estrogen or raloxifene.
    Posritong S; Hong JM; Eleniste PP; McIntyre PW; Wu JL; Himes ER; Patel V; Kacena MA; Bruzzaniti A
    Mol Cell Endocrinol; 2018 Oct; 474():35-47. PubMed ID: 29428397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional activities of estrogen receptor alpha and beta in yeast properties of raloxifene.
    Jisa E; Dornstauder E; Ogawa S; Inoue S; Muramatsu M; Jungbauer A
    Biochem Pharmacol; 2001 Oct; 62(7):953-61. PubMed ID: 11543731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditioned medium of estrogen-treated osteoblasts inhibits osteoclast maturation and function in vitro.
    Qu Q; Härkönen PL; Mönkkönen J; Väänänen HK
    Bone; 1999 Aug; 25(2):211-5. PubMed ID: 10456387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: estrogen receptor dependent or independent pathways of raloxifene.
    Miki Y; Suzuki T; Nagasaki S; Hata S; Akahira J; Sasano H
    J Steroid Biochem Mol Biol; 2009 Feb; 113(3-5):281-9. PubMed ID: 19429434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies.
    Rogers A; Clowes JA; Pereda CA; Eastell R
    Bone; 2007 Jan; 40(1):105-10. PubMed ID: 16934544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17beta-estradiol downregulates beta3-integrin expression in differentiating and mature human osteoclasts.
    Saintier D; Burde MA; Rey JM; Maudelonde T; de Vernejoul MC; Cohen-Solal ME
    J Cell Physiol; 2004 Feb; 198(2):269-76. PubMed ID: 14603529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of estradiol, methyl-piperidino-pyrazole, raloxifene, and ICI 182 780 on gene expression in the murine uterus.
    Davis AM; Mao J; Naz B; Kohl JA; Rosenfeld CS
    J Mol Endocrinol; 2008 Oct; 41(4):205-17. PubMed ID: 18632874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
    Cheung J; Mak YT; Papaioannou S; Evans BA; Fogelman I; Hampson G
    J Endocrinol; 2003 Jun; 177(3):423-33. PubMed ID: 12773123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A low dose of daidzein acts as an ERbeta-selective agonist in trabecular osteoblasts of young female piglets.
    De Wilde A; Lieberherr M; Colin C; Pointillart A
    J Cell Physiol; 2004 Aug; 200(2):253-62. PubMed ID: 15174095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fluid shear stress and raloxifene stimulates the proliferation of osteoblast through regulating the expresstion of β-catenin and estrogen receptor α].
    Tang WR; Liu Y; Li LH; Wu ZB; He Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Nov; 45(6):913-8. PubMed ID: 25571714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.